Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting#Replimune #Presents #Analyses #IGNYTE #Study #RP1 #Nivolumab #AntiPD1 #Failed #Melanoma #American #Society #Clinical #Oncology #ASCO #Annual #Meeting